Bo-eric P. Persson

St Persgatan 17, 5
Uppsala, C 75320, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Heparin-binding protein as a biomarker of post-injury sepsis in trauma patients.

Heparin-binding protein as a biomarker of post-injury sepsis in trauma patients.

Journal: Acta anaesthesiologica Scandinavica

Published: September 18, 2017

Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.

Journal: Therapeutic advances in urology

Published: April 02, 2016

Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27).

Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27).

Journal: Therapeutic advances in urology

Published: July 11, 2015

Reply by the authors.

Reply by the authors.

Journal: Urology

Published: August 05, 2014

Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.

Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.

Journal: European urology

Published: March 11, 2014

Heparin-binding protein (HBP/CAP37) - a link to endothelin-1 in endotoxemia-induced pulmonary oedema?

Heparin-binding protein (HBP/CAP37) - a link to endothelin-1 in endotoxemia-induced pulmonary oedema?

Journal: Acta anaesthesiologica Scandinavica

Published: February 07, 2014

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

Journal: Urology

Published: October 18, 2013

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Journal: European urology

Published: August 23, 2013

Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.

Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.

Journal: The Journal of urology

Published: September 10, 2012

Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.

Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.

Journal: Asian journal of andrology

Published: August 21, 2012

Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).

Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).

Journal: Urologia internationalis

Published: July 06, 2012

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Journal: Urology

Published: December 05, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026